Download

Disease/health condition - Hepatitis B virus (HBV) infection
Hepatitis B e antigen (HBeAg)
Assay format
Immunoassay
Information History
First added in 2018
Changed in 2024
Purpose type
Staging, Treatment selection
Purpose
To stage chronic HBV infection, to determine the need for treatment together with ALT measurement, and as a criterion for use of antivirals in pregnant women to prevent mother-to-child transmission.* .
* This test should be used only when HBV DNA testing is not available
Specimen types
Serum, Plasma
WHO prequalified or recommended products
N/A
GMDN

48330

Hepatitis B virus e-antigen IVD, kit, enzyme immunoassay (EIA)

A collection of reagents and other associated materials intended to be used for the qualitative and/or quantitative detection of Hepatitis B virus e-antigen in a clinical specimen, using an enzyme immunoassay (EIA) method.

The medical device term(s), code(s) and definition(s) in this section were retrieved from databases external to WHO. As there might be more than one name, definition and “Nomenclature Code” related to the specific medical device, please consult https://gmdnagency.org GMDN ®. © GMDN Agency 2005-2024
EMDN

W0105020299

HBV REAGENTS - OTHER

The code(s) and term(s) in this section were observed and retrieved from public databases and have not been validated by health regulatory authorities. Please consult your regulatory agency and EMDN site: https://webgate.ec.europa.eu/dyna2/emdn
WHO supporting publications
World Health Organization. (‎2017)‎. WHO guidelines on hepatitis B and C testing. World Health Organization. https://iris.who.int/handle/10665/254621 ; World Health Organization. (‎2024)‎. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. World Health Organization. https://iris.who.int/handle/10665/376353
Technical specifications
This tool presents technical specifications for 16 IVD tests for HBV. To review the one(s) of your interest, download the file and go to the “Test menu” tab to make your selection. You will find more details in the “Content” tab of this file.
SAGE IVD recommended including this test in the EDL on the basis of the scientific validity of the analyte and the availability of WHO guidelines and technical reports, including recommendations for the use of this test. The selection of disease specific tests for the EDL also took into account relevant priority diseases for WHO such as NCDs including DM, CVD and cancer, HIV infection, malaria, NTDs, STIs, tuberculosis, viral hepatitis B and C, among others.
N/A
The inclusion of this test was based on WHO guidelines and/or technical documents that include recommendations for the use of this test.
N/A